AbCellera Biologics Inc.
ABCL
$3.13
-$0.10-3.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -57.45% | -44.98% | -1.39% | -27.18% | -18.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -57.45% | -44.98% | -1.39% | -27.18% | -18.36% |
| Cost of Revenue | 8.17% | -5.24% | 8.05% | 12.21% | -25.38% |
| Gross Profit | -30.44% | -4.01% | -10.04% | -27.21% | 27.49% |
| SG&A Expenses | -7.96% | 0.47% | 24.92% | 20.48% | 9.58% |
| Depreciation & Amortization | 10.05% | -357.90% | 543.75% | 551.02% | -12.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.16% | -39.12% | 62.91% | 64.01% | -15.85% |
| Operating Income | -14.15% | 38.30% | -70.64% | -81.86% | 15.38% |
| Income Before Tax | -23.95% | 3.65% | -59.47% | -26.79% | 11.22% |
| Income Tax Expenses | -244.55% | -769.08% | -8.05% | -50.58% | 73.41% |
| Earnings from Continuing Operations | -12.34% | 27.44% | -78.63% | -20.97% | -1.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.34% | 27.44% | -78.63% | -20.97% | -1.25% |
| EBIT | -14.15% | 38.30% | -70.64% | -81.86% | 15.38% |
| EBITDA | -14.54% | 55.50% | -15.44% | -24.36% | 15.68% |
| EPS Basic | -10.45% | 28.69% | -75.40% | -18.73% | 0.50% |
| Normalized Basic EPS | -21.80% | 46.62% | -97.76% | -18.37% | 12.72% |
| EPS Diluted | -9.43% | 31.80% | -73.30% | -18.18% | 0.00% |
| Normalized Diluted EPS | -21.80% | 46.62% | -97.76% | -18.37% | 12.72% |
| Average Basic Shares Outstanding | 1.70% | 1.76% | 1.85% | 1.84% | 1.72% |
| Average Diluted Shares Outstanding | 1.70% | 1.76% | 1.85% | 1.84% | 1.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |